Zan is ‘worth’ far more even than that, but it’s far from certain shareholders will pocket the value. It seems perfectly sane and sober to envisage a notional ‘value’ - once clinically validated - larger than the MC of a BP, and well beyond the means of anyone to pay outright. IMO we should be planning not to sell, but to rent out IP as a string of licensing deals with individual BPs.
This is of course not the norm for a rising bio-spec, which is meant to feel ‘amazed’ and grateful at a large buyout. But RAC is not the norm, with potentially far greater shareholder cohesion and hence negotiating options.
Zan is ‘worth’ far more even than that, but it’s far from...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.79 |
Change
-0.075(4.02%) |
Mkt cap ! $304.8M | |||
| Open | High | Low | Value | Volume |
| $1.86 | $1.86 | $1.76 | $348.2K | 192.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5612 | $1.77 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.79 | 3567 | 1 |
View Market Depth
| Last trade - 16.10pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.78 |
Change
-0.075 ( 5.38 %) |
||||
| Open | High | Low | Volume | ||
| $1.81 | $1.86 | $1.76 | 27553 | ||
| Last updated 15.55pm 14/06/2024 ? | |||||
| RAC (ASX) Chart |